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Psoriasis May Not be an Independent Risk Factor
for Acute Ischemic Heart Disease Hospitalizations:
Results of a Large Population-Based Dutch Cohort
Marlies Wakkee1, Ron M.C. Herings2,3 and Tamar Nijsten1
Although psoriasis has been associated with components of the metabolic syndrome, its association with
myocardial infarction is less clear. A cohort study was conducted using hospital and pharmacy records of 2.5
million Dutch residents between 1997 and 2008. The risk of ischemic heart disease (IHD) hospitalizations was
compared between psoriasis patients and a matched reference cohort. Additional adjustments were made for
healthcare consumption and use of cardiovascular drugs. A total of 15,820 psoriasis patients and 27,577
reference subjects were included, showing an incidence rate of 611 and 559 IHD per 100,000 person-years,
respectively (P¼ 0.066). The age- and gender-adjusted risk of IHD was comparable between both cohorts
(hazard ratio (HR)¼ 1.10, 95% confidence interval 0.99–1.23). Before cohort entry, psoriasis patients used more
antihypertensive, antidiabetic, and lipid-lowering drugs and were more often hospitalized. Adjusting for these
confounders decreased the HR for IHD, but it remained comparable between both populations. There was no
different risk of IHD between the subgroup of patients who only used topicals versus those who received
systemic therapies or inpatient care for their psoriasis. This study, therefore, suggests that psoriasis is not a
clinically relevant risk factor for IHD hospitalizations on the population level.
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INTRODUCTION
In the past 5 years, the interest in the association between
psoriasis and comorbidities, especially cardiovascular dis-
eases, has revived (Gelfand et al., 2006; Neimann et al.,
2006; Cohen et al., 2007; Wakkee et al., 2007; Kimball et al.,
2008; Wakkee and Nijsten, 2009). Several observational
studies found an increased risk of cardiovascular diseases.
The primary underlying hypothesis is that the increased
systemic inflammatory status of psoriasis patients leads to
and/or aggravates other chronic (low-grade) inflammatory
diseases including atherosclerosis. However, psoriasis is also
associated with a considerable health-related quality of life
impairment, depression, altered life styles, increased use of
systemic drugs, and healthcare consumption, which may
affect the relationship between psoriasis and the metabolic
syndrome as well (Nijsten and Wakkee, 2009; Wakkee and
Nijsten, 2009). Although several studies adjusted in part for
potential confounders, such as diabetes, dyslipidemia,
obesity, and smoking, residual confounding may be sub-
stantial (Nijsten and Wakkee, 2009; Wakkee et al., 2009).
More recently, psoriasis has been associated with an
increased risk of myocardial infarction (MI) using the data from
the UK general practice research database (GPRD) (Gelfand
et al., 2006; Kaye et al., 2008). Another study analyzing the
same cohort could not confirm an overall increased risk of MI
(Brauchli et al., 2009). Moreover, a Swedish population-based
study found that the risk of MI was only increased in females
with psoriasis, whereas another US study observed a particu-
larly higher rate of occlusive vascular disease in male psoriasis
patients (McDonald and Calabresi, 1973; Lindegard, 1986). In
the PUVA (psoralen plus ultraviolet light A) Follow-Up Study,
cardiovascular mortality was comparable with the expected
incidence (Stern and Lange, 1988).
Although psoriasis is associated with components of the
metabolic syndrome, its association with MI is still less clear.
The objective of this study was therefore to conduct an
exploratory study on the association between psoriasis and
ischemic heart disease (IHD) by comparing the incidence of
hospitalizations for IHD in psoriasis patients with controls in
a large sample of the Dutch population using hospital and
pharmacy-linked databases.
RESULTS
Study population
The cohort study included 43,397 subjects of whom 15,820
(37%) had psoriasis. The mean age at cohort entry was
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between 48 and 49 years and 52% were female (Table 1).
Psoriasis patients were significantly more likely to have been
hospitalized for non-cardiovascular diseases in the 6 months
before start of follow-up (7.1 versus 5.1%, Po0.001) and to
have filled prescriptions for lipid-lowering, antihypertensive,
and antidiabetic drugs.
Almost all patients with psoriasis had used a topical
antipsoriatic therapy (99%), and 13% had used a systemic
antipsoriatic therapy or were hospitalized for their psoriasis.
Event rate and univariate analyses
The median follow-up time was about 6 years in both
cohorts. In the psoriasis population, 3.7% were hospitalized
for an IHD (583 events) resulting in an incidence rate of 611
IHDs (95% confidence interval (CI) 562–663) per 100,000
person-years (Table 2). In the matched cohort population,
846 IHDs occurred in 3.1% of the controls representing an
incidence rate of 559 IHDs (95% CI 522–598) per 100,000
person-years. Psoriasis patients and controls had an equal
likelihood of developing an IHD in time (P¼ 0.066, Figure 1).
The age- and gender-matched hazard ratio (HR) for IHD was
borderline significantly increased for psoriasis (crude HR
1.10, 95% CI 0.99–1.23).
Acute MIs were observed 234 and 235 times per 100,000
person-years in the psoriasis and control cohort, respectively.
The age- and gender-adjusted survival analysis did not show a
different risk of acute MI (crude HR 0.99, 95% CI 0.84–1.17).
Multivariate survival analyses
The risk of IHD decreased but remained comparable between
the psoriasis and reference cohort (adjusted HR 1.05, 95% CI
0.95–1.17, Table 2) after adjusting for the healthcare
consumption proxy, metabolic drugs, and an interaction
term between psoriasis and healthcare consumption. The
multivariate model for MI, which did not include any
significant interaction variables, showed that psoriasis was
not associated with a different risk of acute MI.
Sensitivity analyses
Restricting the analysis to individuals without cardiovascular
disease-associated hospitalizations in their 6 months history
showed that the risk of developing an IHD remained
comparable between psoriasis patients and matched refer-
ences (crude HR 1.09, 95% CI 0.98–1.22).
In the cohort of psoriasis patients, those who had used
PUVA, systemic antipsoriatic therapies, or were treated as in
patients had no different risk of IHD than the psoriasis
patients who had only used topical therapies (P¼ 0.10).
Stratifying for age group showed that the HRs of 35,509
people of 65 years or younger and 7,888 persons older than
65 years (HR 1.06, 95% CI 0.92–1.23 and HR 1.09, 95% CI
0.93–1.28, respectively) were comparable with the HRs of the
total population.
DISCUSSION
The results of this large cohort study with valid and clinically
relevant outcomes suggest that psoriasis is not a risk factor for
acute IHD hospitalizations on the population level. Psoriasis
Table 1. Baseline characteristics of the psoriasis and
reference cohorts
Variable Psoriasis cohort Reference cohort
No. (%) 15,820 (36.5) 27,577 (63.5)
Gender
Male (%) 7,583 (47.9) 13,306 (48.3)
Female (%) 8,237 (52.1) 14,271 (51.7)
Age in years
Mean (SD) 48.9 (16.1) 48.1 (16.1)
Earlier hospitalizations1
Yes (%) 1,130 (7.1%)2 1,415 (5.1%)2
Total 1,676 1,979
Unique 1,447 1,802
Medical history1
Lipid-lowering drugs (%) 1,102 (7.0)3 1,701 (6.2)3
Antihypertensive drugs (%) 3,076 (19.4)4 4,519 (16.4)4
Antidiabetic drugs (%) 699 (4.4)4 993 (3.6)4
Psoriasis therapies
Topicals only 13,851 (87.5)
Systemic therapy and/or
hospitalization5
1,969 (12.5)
Specific therapies ever used since start of follow-up6
Topical antipsoriatic 15,646 (98.9)
Therapies7
PUVA therapy 505 (3.2)
Methotrexate 122 (0.8)
Ciclosporin 424 (2.7)
Acitretin 789 (5.0)
Fumarates 14 (0.1)
Biologics8 84 (0.5)
PUVA, psoralen plus ultraviolet light A; SD, standard deviation.
1In 6 months before cohort entry (excluding hospitalizations for
cardiovascular diseases, n=100 and n=124 for the psoriasis and control
cohorts, respectively).
2Po0.001.
3P=0.001.
4Po0.001.
5Systemic drugs include PUVA therapy, and hospitalization should be
specific for psoriasis.
6Total adds up to more than 100% because of the possibility of multiple
therapies per patient.
7Coal tar, topical corticosteroids, dithranol, calcipotriol, calcitriol,
tacrolimus, and pimecrolimus.
8Adalimumab (n=19), efalizumab (n=8), etanercept (n=65), infliximab
(n=2).
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patients initially seemed to have an increased risk of IHD, but
after adjusting for metabolic drug use and healthcare
consumption, this association seemed to be strongly affected
by confounding. We observed that psoriasis patients may
have a different cardiovascular risk profile for which they
receive subsequent therapies, and that the risk of IHD and MI
were similar to the reference population. This may seem
contradictory, but it has previously been shown that there is a
weak or even no association between the metabolic
syndrome and the occurrence of cardiovascular events (Sattar
et al., 2008). This corresponds with a prospective cohort
study of mortality causes among psoriasis patients, which
showed no increased cardiovascular mortality (Stern and
Lange, 1988).
Our data differ from the interpretations of the results of the
study performed in the GPRD by Gelfand et al. (2006).
Despite these differences, the factual information between
the GPRD-based study and our study is marginal. Their HRs
for MI were 1.11 (95% CI 1.07–1.17) for mild psoriasis and
1.43 (95% CI 1.18–1.72) for severe psoriasis (Gelfand et al.,
2006). Moreover, another recent cohort study of the GPRD
on incident psoriasis patients could not confirm previous
GPRD findings and showed no overall increased risk of
incident MI in psoriasis (Brauchli et al., 2009). The risk of
IHD tended to be increased in our study, but the analyses of
our data suggest that other factors, for example, referral bias
for other disease, are important for interpretation of our
results. It might well be that the results that were found in the
GPRD study have been biased likewise.
On the basis of the theory that a high inflammatory state
accelerates the atherosclerotic process and increases the risk
of cardiovascular events, one might expect a relationship
between the severity of psoriasis and the occurrence of IHD.
By using the applied therapies as proxies for psoriasis
severity, our data did not show a different risk of IHD
between patients with more severe psoriasis (that is, systemic
antipsoriatic therapies or inpatient treatments) compared with
mild psoriatic patients (that is, only topicals), even after
adjusting for confounders. However, using a secondary
database does not allow us to draw any conclusions about
the natural history of longstanding uncontrolled severe
psoriasis.
We also found that psoriasis patients generally use more
healthcare than ‘‘healthy’’ individuals. This may increase the
risk of diagnosing other conditions such as cardiovascular
diseases, for which additional drugs may be prescribed or
patients are hospitalized (Wakkee et al., 2009). MIs are, for
example, asymptomatic or clinically unrecognized in
21–68% of all cases (Aronow, 2003; de Torbal et al., 2006).
As testing for interaction showed a significant interaction
between psoriasis and the number of earlier hospitalizations,
we reduced surveillance bias and assured a more equal
comparison between cohorts by adjusting for this healthcare
consumption variable. Remarkably, most other studies
investigating the risk of cardiovascular events among
psoriasis patients did not examine whether surveillance bias
Table 2. Incidence rates of ischemic heart disease (IHD) and acute myocardial infarction (MI) in patients with
psoriasis and the reference cohort, and the crude and adjusted hazard ratios (HRs)
Outcome Events Person-years Incidence rate1 95% CI Crude HR2 95% CI Adjusted HR3 95% CI
IHD4
Reference cohort 846 151,303 559 522, 598 1 1
Psoriasis cohort 583 95,437 611 562, 663 1.10 0.99, 1.23 1.05 0.95, 1.17
Acute MI
Reference cohort 360 153,514 235 211, 260 1 1
Psoriasis cohort 223 97,029 234 201, 262 0.99 0.84, 1.17 0.94 0.80, 1.11
CI, confidence interval.
1Incidence rate per 100,000 person-years.
2HR adjusted for age and gender by matching.
3Adjusted for age, gender, earlier use of antihypertensive, antidiabetic, and lipid-lowering drugs, the number of earlier non-cardiovascular hospitalizations in
180 days before cohort entry, and significant interaction terms.
4IHD includes hospitalizations for acute myocardial infarction, angina pectoris, and other acute IHDs.
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Figure 1. Crude survival for ischemic heart disease (IHD) for patients
with psoriasis and the age- and gender-matched reference cohort:
results of the Kaplan–Meier analysis.
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may have influenced their results. Nevertheless, this hospital-
and pharmacy-based study did not have patient character-
istics data such as type of psoriasis, body mass index,
socioeconomic status, and life-style factors. The absence of
these and other unknown risk factors for IHD may, thus, have
led to overestimated risk estimates (Nijsten and Wakkee,
2009).
In this large population-based cohort study, clinically
relevant outcomes of cardiovascular disease based on
hospital discharge diagnosis were used as end points. The
PHARMO Record Linkage System collected data prospec-
tively and irrespective of our hypothesis, which excludes
recall bias. The longitudinal National Medical Register, from
which the hospital data were extracted, has almost complete
coverage (99%) of all hospital admissions in the Netherlands.
The observed MI incidence in the reference population was
comparable with that estimated by the Dutch Heart Associa-
tion in the Dutch population (235 versus 227 per 100,000
person-years, respectively), confirming the validity of the
study outcome (Dutch Heart Association, 2009). The out-
comes we studied are somewhat different from the GPRD
study in which MI diagnoses were based on GP data, which
may be more sensitive to misclassification basis than
hospitalization records (Hammad et al., 2008).
A caveat of our study was that we based the definition of
psoriasis on drug and hospitalization records, potentially
resulting in misclassification, and hence, regression to the nil
to show exposure-related disease. The prevalence of actively
treated psoriasis patients was 0.6% (15,820 subjects). As
expected, this was lower than the estimated psoriasis
prevalence of 2–3% in Western populations that includes
patients without prescription drugs (Stern et al., 2004; Nijsten
et al., 2005). Psoriasis patients without psoriasis-specific
therapies, such as vitamin-D derivatives, PUVA, or inpatient
treatments, were also missed in this study. However, those
subjects who had only used possible drug dispensings for
psoriasis, such as corticosteroids or methotrexate, were also
excluded from the reference cohort. The prevalence of more
severe psoriasis was 13% in the psoriasis cohort, which is
more in line with a recent estimate of 17% moderate-to-
severe psoriasis in the US adults than the 3% severe psoriasis
patients observed in the GPRD data set (Gelfand et al., 2006;
Kurd and Gelfand, 2009). However, this therapy-based
classification of severity remains a proxy, as no data were
available on clinical disease severity. Validation of our
psoriasis definition by GP medical files has been described
in detail, and showed an excellent sensitivity of 98.2% and
good specificity of 80.2% (Wakkee et al., 2009). Hence, we
have no reason to believe that we underestimated the risk of
cardiovascular disease among patients with psoriasis. A
sensitivity analysis that excluded all patients with a cardio-
vascular event in the 6 months before cohort entry showed
comparable results.
Our data showed only a slight and borderline-significant
increased risk of IHD among psoriasis patients. We reason
that this association resulted from residual confounding such
as increased healthcare consumption. Previous studies in
which psoriasis was found to be an independent risk factor
for cardiovascular events may have been biased likewise.
Owing to the modest positive association between psoriasis
and cardiovascular diseases, correction for confounders is
critical and requires prospective studies designed to address
this research hypothesis. Of course, clinicians should be
attentive for risk factors or internal conditions that can affect
their patients’ health other than their skin disease.
MATERIALS AND METHODS
Data source
For this study, we used data from the PHARMO Record Linkage
System, which links various medical databases including those on
hospital discharge information, drug dispensing, and clinical
laboratory records concerning 2.5 million individuals who were or
have been the residents in defined areas in the Netherlands (Lau
et al., 1997; Herings et al., 1999, 2000; Erkens et al., 2005; Pharmo,
2009). The hospital records included detailed information on
primary and secondary diagnoses (coded according to the Interna-
tional Classification of Diseases, ninth Revision (WHO, 1987)),
medical procedures, and dates of hospital admission and discharge.
The drug dispensing records (coded according to the Anatomical
Therapeutic Chemical Classification) (WHO, 1999) consisted of the
dispensing date, amount dispensed, and prescription dose regimens
and length.
Study population
Patients with psoriasis were identified from the Pharmo Record
Linkage System database using a five-step algorithm that focused on
maximizing case sensitivity based on hospitalizations and drug
dispensing records. This algorithm categorized individuals according
to the likelihood of having been diagnosed with psoriasis (none,
possible, probable, or definite), from which only those who
definitely had psoriasis were selected. In the algorithm, individuals
with a hospital discharge diagnosis of psoriasis and/or psoriatic
arthritis, dispensings for psoralen, calcipotriol, calcitriol or dithranol,
fumaric acid, and/or efalizumab were considered as definite
psoriasis patients. Patients were classified as possibly or probably
having psoriasis if they did not meet any of the abovementioned
criteria, but had prescriptions for topical corticosteroids, coal tar,
systemic glucocorticosteroids, retinoids, methotrexate, ciclosporin,
adalimumab, etanercept, and/or infliximab. UV-B was not assessed,
because this therapy is administered without pharmacy prescription. In
the last step of the algorithm, identified definite psoriasis patients were
excluded if they had been hospitalized for skin conditions other than
psoriasis, hado6 months of history before start of follow-up (which is
twice the maximum prescription time allowed in the Netherlands),
and/or were o18 years of age at index date. Patients were also
excluded if they had a history of diseases that could, theoretically,
affect the development of psoriasis or its severity (that is, HIV, immune
disorders, inflammatory bowel diseases, hepatitis B and C, multiple
sclerosis, rheumatoid arthritis, and status after organ transplant).
From the pool of people with no likelihood of having psoriasis,
reference subjects were selected and matched in a 1:2 ratio for age,
gender, and presence of a database record within 30 days of cohort
entry of a definite psoriasis patient. Similar to the psoriasis patients,
reference subjects were excluded if o6 months of history was
available or if they were hospitalized for dermatological diseases or
the conditions listed above.
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Follow-up period
Patients with psoriasis were followed from the first available date of
an active treatment or hospitalization for psoriasis between 1998 and
2007. Subjects in the comparison cohort were followed from
random drug dispensing or hospitalization occurring within 30 days
of the start of follow-up of their matched psoriasis patient. For all
subjects, follow-up time ended with the last drug dispensing
available before 2008, an IHD, or death, whichever came first.
Study outcomes
The primary study outcome was hospitalization for acute IHD (that
is, acute MI, other acute IHD, and angina pectoris). In addition,
acute MI was studied separately.
Potential confounders
For each subject, we explored dispensings of antihypertensives,
lipid-lowering, and antidiabetic drugs in 6 months before cohort
entry to provide a proxy for the presence of treated dyslipidemia,
hypertension, and diabetes mellitus. To adjust for healthcare
utilization, we calculated the total number of hospitalizations
(except for cardiovascular diseases to avoid overadjustment) in 6
months before cohort entry (Smitten et al., 2008). No information
was available on life-style factors such as physical exercise, diet,
smoking, alcohol consumption, or health-related quality of life.
Statistical analysis
Continuous variables are presented as means (standard deviations) or
median (interquartile range) and were tested for statistically signifi-
cant differences using the Student’s t-test and the Mann–Whitney
test, respectively. Incidence rates and 95% CIs, which were
calculated using Byar’s approximation (Breslow and Day, 1987),
are presented as events per 100,000 person-years. Kaplan–Meier,
and univariate and multivariate Cox proportional hazard analyses
were performed to compare the likelihood of registrating the study
outcome between the two cohorts. Owing to age and gender
matching, the ‘‘crude’’ HRs already take into account these potential
confounders. Biologically plausible and available confounding
variables such as antihypertensives, antidiabetic and lipid-lowering
drug use, and number of hospitalizations in 180 days before cohort
entry, all changed the HR for psoriasis by 10% or more in the
bivariate analyses and were therefore included in the multivariate
model (von Elm et al., 2007). In the multivariate model, these
confounders were also tested for interaction with psoriasis. Visual
inspection of the log(log) survival plots against time that confirmed
the proportional hazard assumptions were met.
Several sensitivity analyses were performed. First, the analyses
were restricted to patients without a cardiovascular event in the
6 months before cohort entry to increase the likelihood of examining
incident events. Effect modification by age on the risk estimates was
explored by stratification for age (p65 and 465 years) and by
testing for interaction with psoriasis. Subgroup survival analyses
were conducted to analyse whether there was a different risk of IHD
between psoriasis patients who only used topical therapies versus
those who used PUVA, systemic antipsoriatic drugs, and/or were
hospitalized. All statistical tests were two-sided and a P-valueo0.05
was considered statistically significant. The analyses were performed
using SPSS 15.0 (SPSS, Chicago, IL). Adherence to the STROBE
(The Strengthening the Reporting of Observational Studies in
Epidemiology) guidelines, especially for the multivariate analysis,
assured the reporting of this observational study (von Elm et al.,
2007).
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